MCID: BRS044
MIFTS: 58

Breast Adenocarcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Breast Adenocarcinoma

MalaCards integrated aliases for Breast Adenocarcinoma:

Name: Breast Adenocarcinoma 12 29 6 15 17 71
Mammary Adenocarcinoma 12 71
Adenocarcinoma of Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3458
NCIt 50 C5214
UMLS 71 C0858252 C3669246

Summaries for Breast Adenocarcinoma

Disease Ontology : 12 A breast carcinoma that originates in the milk ducts and/or lobules (glandular tissue) of the breast.

MalaCards based summary : Breast Adenocarcinoma, also known as mammary adenocarcinoma, is related to mammary paget's disease and inflammatory breast carcinoma. An important gene associated with Breast Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Zoledronic Acid and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include breast, endothelial and lymph node, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Breast Adenocarcinoma

Diseases in the Breast Adenocarcinoma family:

Rare Adenocarcinoma of the Breast

Diseases related to Breast Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 481)
# Related Disease Score Top Affiliating Genes
1 mammary paget's disease 32.5 TNFSF11 ESR1 ERBB2 EGFR
2 inflammatory breast carcinoma 32.5 ESR1 ERBB2 EGFR
3 oncocytic breast carcinoma 32.4 ESR1 ERBB2
4 adenocarcinoma 31.6 TP53 PIK3CA MYC MMP9 MMP2 KRAS
5 breast disease 31.0 TP53 TNF ESR1 ERBB2 EGF BAX
6 glioblastoma 30.9 TP53 PIK3CA MYC MMP2 H19 ERBB2
7 prostatic hypertrophy 30.9 ESR1 EGFR EGF
8 b-cell lymphoma 30.9 TP53 MYC CASP9 CASP8 BAX
9 ductal carcinoma in situ 30.9 TP53 PIK3CA MYC MMP9 ESR1 ERBB2
10 in situ carcinoma 30.9 TP53 PIK3CA MYC ESR1 ERBB2 EGFR
11 glioma 30.8 TP53 PIK3CA MMP9 MMP2 H19 ERBB2
12 bone cancer 30.8 TP53 TNFSF11 MMP9 ESR1 EGFR CYCS
13 comedo carcinoma 30.8 TP53 ESR1 ERBB2
14 squamous cell carcinoma 30.7 TP53 PIK3CA MYC MMP9 MMP2 H19
15 osteogenic sarcoma 30.7 TP53 TNFSF11 TNF MYC MMP9 MMP2
16 breast ductal carcinoma 30.7 TP53 MMP9 ESR1 ERBB2 EGFR
17 apocrine adenocarcinoma 30.7 TP53 ESR1 ERBB2
18 female breast cancer 30.6 TP53 TNF ESR1 ERBB2
19 basal cell carcinoma 30.6 TP53 TNF MMP9 MMP2 EGFR BAX
20 cystadenocarcinoma 30.6 TP53 PIK3CA ERBB2 AKT1
21 fibrosarcoma 30.6 TP53 TNF MYC MMP9 MMP2
22 retinitis pigmentosa 11 30.6 TP53 MYC ERBB2 EGFR
23 suppression of tumorigenicity 12 30.6 TP53 PIK3CA MYC ERBB2 EGFR EGF
24 tubular adenocarcinoma 30.6 ESR1 ERBB2 EGFR
25 breast fibroadenoma 30.6 TP53 ESR1 ERBB2
26 polycystic kidney disease 30.6 TP53 TNF MYC MMP9 ERBB2 EGFR
27 oral squamous cell carcinoma 30.6 TP53 MMP9 MMP2 H19 EGFR AKT1
28 bone resorption disease 30.6 TNFSF11 TNF ESR1
29 sarcoma 30.5 TP53 PIK3CA MYC KRAS CYCS CASP9
30 hepatocellular carcinoma 30.5 TP53 TNF PIK3CA MYC MMP9 MMP2
31 estrogen-receptor positive breast cancer 30.5 TP53 PIK3CA MYC ESR1 ERBB2 EGFR
32 colorectal adenocarcinoma 30.5 TP53 MYC MMP2 KRAS ERBB2 EGFR
33 meningioma, familial 30.5 TP53 PIK3CA H19 ESR1 EGFR EGF
34 renal cell carcinoma, nonpapillary 30.5 TP53 PIK3CA MMP9 MMP2 H19 EGFR
35 colon adenocarcinoma 30.5 TP53 TNF PIK3CA MYC KRAS ESR1
36 intrahepatic cholangiocarcinoma 30.5 TP53 MMP9 KRAS ERBB2 EGFR
37 neuroblastoma 30.5 TP53 TNF PIK3CA MYC MMP9 MMP2
38 medulloblastoma 30.5 TP53 PIK3CA MYC MMP9 H19 ERBB2
39 small cell carcinoma 30.4 TP53 KRAS ERBB2 EGFR
40 signet ring cell adenocarcinoma 30.4 TP53 KRAS ERBB2
41 t-cell lymphoblastic leukemia/lymphoma 30.4 MYC CYCS CASP9 CASP8 AKT1
42 lung cancer susceptibility 3 30.4 TP53 PIK3CA MYC MMP9 MMP2 KRAS
43 ovarian cystadenocarcinoma 30.4 TP53 PIK3CA MYC KRAS ERBB2 EGFR
44 gastric adenocarcinoma 30.4 TP53 PIK3CA MYC KRAS H19 ERBB2
45 rhabdomyosarcoma 30.4 TP53 TNF SLC22A18 PIK3CA MYC MMP2
46 pancreatic cancer 30.4 TP53 TNF PIK3CA MYC MMP9 MMP2
47 teratoma 30.4 TP53 KRAS ESR1 AKT1
48 papilloma 30.3 TP53 KRAS ERBB2 EGFR AKT1
49 gastrointestinal stromal tumor 30.3 TP53 MMP9 MMP2 KRAS ERBB2 EGFR
50 cervical squamous cell carcinoma 30.3 TP53 PIK3CA MYC MMP2 KRAS EGFR

Graphical network of the top 20 diseases related to Breast Adenocarcinoma:



Diseases related to Breast Adenocarcinoma

Symptoms & Phenotypes for Breast Adenocarcinoma

GenomeRNAi Phenotypes related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 35)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.39 EGFR PIK3CA KRAS
2 Decreased viability GR00055-A-2 10.39 EGFR PIK3CA KRAS
3 Decreased viability GR00055-A-3 10.39 KRAS
4 Decreased viability GR00106-A-0 10.39 KRAS
5 Decreased viability GR00221-A-1 10.39 AKT1 EGFR ESR1 PIK3CA KRAS MYC
6 Decreased viability GR00221-A-2 10.39 AKT1 ESR1 PIK3CA KRAS
7 Decreased viability GR00221-A-3 10.39 AKT1 ERBB2 MYC
8 Decreased viability GR00221-A-4 10.39 AKT1 EGFR ERBB2 ESR1 PIK3CA
9 Decreased viability GR00249-S 10.39 AKT1 MYC
10 Decreased viability GR00301-A 10.39 KRAS
11 Decreased viability GR00381-A-1 10.39 KRAS
12 Decreased viability GR00386-A-1 10.39 ESR1
13 Decreased viability GR00402-S-2 10.39 ESR1 PIK3CA MYC
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.2 PIK3CA
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-146 10.2 CASP8
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.2 ERBB2
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-157 10.2 PIK3CA
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-16 10.2 AKT1 PIK3CA
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-163 10.2 ERBB2
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 10.2 PIK3CA
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.2 MYC
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.2 AKT1 PIK3CA
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 10.2 PIK3CA
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-2 10.2 CASP8
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.2 PIK3CA
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-42 10.2 AKT1 PIK3CA
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 10.2 PIK3CA
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-50 10.2 AKT1
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.2 PIK3CA
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.2 CASP8
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 10.2 MYC
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-79 10.2 AKT1
33 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 AKT1 CASP9 SLC22A18 TNF
34 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 AKT1 BAX CASP9 SLC22A18 TNF TP53
35 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.44 BAX CASP8 TP53

MGI Mouse Phenotypes related to Breast Adenocarcinoma:

46 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.5 AKT1 BAX CASP8 CASP9 CYCS EGF
2 cardiovascular system MP:0005385 10.49 AKT1 CASP8 CASP9 CYCS EGFR ERBB2
3 cellular MP:0005384 10.48 AKT1 BAX CASP8 CASP9 CYCS EGFR
4 immune system MP:0005387 10.47 AKT1 BAX CASP8 CASP9 CYCS EGF
5 endocrine/exocrine gland MP:0005379 10.45 AKT1 BAX CASP8 CASP9 CYCS EGF
6 behavior/neurological MP:0005386 10.43 AKT1 BAX CYCS ERBB2 ESR1 KRAS
7 hematopoietic system MP:0005397 10.43 AKT1 BAX CASP8 CASP9 CYCS EGFR
8 homeostasis/metabolism MP:0005376 10.42 AKT1 BAX CASP8 EGFR ERBB2 ESR1
9 mortality/aging MP:0010768 10.41 AKT1 BAX CASP8 CASP9 CYCS EGFR
10 embryo MP:0005380 10.4 AKT1 CASP8 CASP9 CYCS EGFR ERBB2
11 integument MP:0010771 10.37 AKT1 CASP8 EGF EGFR ERBB2 ESR1
12 craniofacial MP:0005382 10.34 CASP9 CYCS EGFR ERBB2 KRAS MMP2
13 muscle MP:0005369 10.33 AKT1 BAX CASP8 EGFR ERBB2 ESR1
14 nervous system MP:0003631 10.31 AKT1 BAX CASP8 CASP9 CYCS EGFR
15 digestive/alimentary MP:0005381 10.29 EGF EGFR ERBB2 ESR1 KRAS MMP9
16 neoplasm MP:0002006 10.28 AKT1 BAX CASP8 EGFR ERBB2 ESR1
17 limbs/digits/tail MP:0005371 10.21 BAX EGFR ERBB2 ESR1 KRAS MMP9
18 liver/biliary system MP:0005370 10.15 AKT1 CASP8 EGFR ESR1 KRAS MYC
19 reproductive system MP:0005389 10.07 AKT1 BAX EGF EGFR ERBB2 ESR1
20 normal MP:0002873 10.06 AKT1 EGF EGFR ERBB2 ESR1 KRAS
21 no phenotypic analysis MP:0003012 10.02 EGFR ESR1 KRAS MYC PIK3CA RB1CC1
22 respiratory system MP:0005388 9.97 AKT1 BAX CASP8 CASP9 EGFR ERBB2
23 skeleton MP:0005390 9.8 AKT1 BAX CYCS EGFR ERBB2 ESR1
24 vision/eye MP:0005391 9.36 BAX EGF EGFR KRAS MMP2 MMP9

Drugs & Therapeutics for Breast Adenocarcinoma

Drugs for Breast Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zoledronic Acid Approved Phase 3 118072-93-8 68740
2
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
3
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
4
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
5
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
6
Pertuzumab Approved Phase 3 380610-27-5, 145040-37-5 2540
7
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
8
Sodium citrate Approved, Investigational Phase 3 68-04-2
9
Tamoxifen Approved Phase 3 10540-29-1 2733526
10
Bevacizumab Approved, Investigational Phase 3 216974-75-3
11
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
12
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
13
Goserelin Approved Phase 3 65807-02-5 47725 5311128
14
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
15
Entinostat Investigational Phase 3 209783-80-2
16 Antimitotic Agents Phase 3
17 Immunologic Factors Phase 3
18 Tubulin Modulators Phase 3
19 Albumin-Bound Paclitaxel Phase 3
20 Immunoglobulins, Intravenous Phase 3
21 Citrate Phase 3
22 Estrogens Phase 3
23 Hormone Antagonists Phase 3
24 Estrogen Receptor Antagonists Phase 3
25 Aromatase Inhibitors Phase 3
26 Hormones Phase 3
27 Estrogen Receptor Modulators Phase 3
28 Estrogen Antagonists Phase 3
29 Antineoplastic Agents, Hormonal Phase 3
30 Immunoglobulin G Phase 3
31 Angiogenesis Inhibitors Phase 3
32 Mitogens Phase 3
33 Endothelial Growth Factors Phase 3
34 Halichondrin B Phase 3
35
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
36
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
37
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
38
Adenosine Approved, Investigational Phase 2 58-61-7 60961
39
Testosterone Approved, Investigational Phase 2 58-22-0 6013
40
Talazoparib Approved, Investigational Phase 2 1207456-01-6 135565082
41
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
42
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
43 Molgramostim Investigational Phase 2 99283-10-0
44
Afimoxifene Investigational Phase 2 68392-35-8
45 Antineoplastic Agents, Immunological Phase 1, Phase 2
46 Immunoconjugates Phase 2
47 Vaccines Phase 2
48 Maytansine Phase 2
49 Ado-trastuzumab emtansine Phase 2
50 Androgens Phase 2

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 Randomized Double-blind Study to Compare Two Neo-adjuvant Treatments: an Anti-aromatase vs SERM for Postmenopausal Women With ER+ Breast Adenocarcinoma: Effect on Intermediate Predictive Biological Response to Treatment. Completed NCT00949598 Phase 3 letrozole;tamoxifen citrate
2 Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer Completed NCT00005970 Phase 3 Aromatase Inhibition Therapy;Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel;Tamoxifen Citrate
3 A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer Completed NCT00869206 Phase 3 zoledronic acid
4 Randomised Multicentric Phase III Study Evaluating the Efficacy of Cicaderma vs Standard Management of Each Site in Preventing Radiodermatitis After Adjuvant Post-operative Breast Irradiation in Patients With Non-metastatic Breast Cancer Recruiting NCT04300829 Phase 3 cicaderma + simple hygiene rules
5 A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer Recruiting NCT02488967 Phase 3 Carboplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel
6 A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer Recruiting NCT03199885 Phase 3 Atezolizumab;Paclitaxel
7 A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer Active, not recruiting NCT00433511 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel
8 Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial Active, not recruiting NCT00310180 Phase 3 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate
9 A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer Active, not recruiting NCT02115282 Phase 3 Entinostat;Exemestane;Goserelin;Goserelin Acetate
10 A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer Suspended NCT02037529 Phase 3 Eribulin Mesylate;Paclitaxel
11 Assessing the Cosmesis and Toxicity of Partial Breast Irradiation Using Proton Beam Irradiation Recruiting NCT01245712 Phase 2
12 Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a PDL-1 Inhibitor in Patients With Triple Negative Breast Cancer Recruiting NCT02530489 Phase 2 Atezolizumab;Nab-paclitaxel
13 T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy Recruiting NCT02957968 Phase 2 Doxorubicin;Cyclophosphamide;Paclitaxel;Carboplatin;Decitabine;Pembrolizumab
14 Phase II Trial to Evaluate Immune-Related Biomarkers for Pathological Response in Stage II-III HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Subsequent Randomization to Multi-Epitope HER2 Vaccine vs. Placebo in Patients With Residual Disease Post-Neoadjuvant Chemotherapy Recruiting NCT04197687 Phase 2
15 Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer Recruiting NCT03106415 Phase 1, Phase 2 Binimetinib
16 A Stratified, Multicenter Phase II Trial of Transdermal CR1447 (4-OH-testosterone) in Endocrine Responsive-HER2 Negative and Triple Negative-androgen Receptor Positive Metastatic or Locally Advanced Breast Cancer Active, not recruiting NCT02067741 Phase 2 CR1447
17 A Pilot Study of Talazoparib as a Neoadjuvant Study in Patients With a Diagnosis of Invasive Breast Cancer and a Deleterious BRCA Mutation Active, not recruiting NCT02282345 Phase 2 Talazoparib
18 A Phase I-II Study of PTX-200 Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Metastatic and Locally Advanced Breast Cancer Terminated NCT01697293 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel;Triciribine Phosphate
19 Combined Modality Radioimmunotherapy For Metastatic Breast Adenocarcinoma With Two Cycles Of Escalating Dose 90Y-DOTA-peptide-m170 and Fixed, Low Dose Paclitaxel With Blood Stem Cell Support And Cyclosporin For HAMA Suppression Unknown status NCT00009763 Phase 1 cyclosporine;paclitaxel
20 A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors Active, not recruiting NCT02453620 Phase 1 Entinostat
21 Phase 1, Multicenter, Open Label Study of DS-8201a to Assess Safety and Pharmacokinetics in Subjects With HER2 Positive Advanced and/or Refractory Gastric, Gastroesophageal Junction Adenocarcinoma, or Breast Cancer Active, not recruiting NCT03368196 Phase 1 DS-8201a
22 Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PET Suspended NCT03432741 Phase 1 Belinostat;Carfilzomib;Fludeoxyglucose F-18;Gemcitabine Hydrochloride;Romidepsin
23 Search for Genetic Factors Predictive of Response to Chemotherapy in Patients With or Who Has a Mammary Adenocarcinoma in Neo-adjuvant or Metastatic Setting Unknown status NCT00959556
24 MUC1/HER-2/Neu Peptide Based Immunotherapeutic Vaccines for Breast Adenocarcinomas Completed NCT00640861 Early Phase 1
25 Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI - The EMBRACE MRI Study Recruiting NCT02306538
26 A Phase 0 Master Protocol Using the CIVO® Platform to Evaluate Intratumoral Microdoses of Anti-Cancer Therapies in Patients With Solid Tumors Not yet recruiting NCT04541108 Early Phase 1 BMS-986299;TAK-676;Cisplatin;5-FU;Paclitaxel

Search NIH Clinical Center for Breast Adenocarcinoma

Genetic Tests for Breast Adenocarcinoma

Genetic tests related to Breast Adenocarcinoma:

# Genetic test Affiliating Genes
1 Breast Adenocarcinoma 29

Anatomical Context for Breast Adenocarcinoma

MalaCards organs/tissues related to Breast Adenocarcinoma:

40
Breast, Endothelial, Lymph Node, Colon, Bone Marrow, T Cells, Skin

Publications for Breast Adenocarcinoma

Articles related to Breast Adenocarcinoma:

(show top 50) (show all 4733)
# Title Authors PMID Year
1
CLAPO syndrome: identification of somatic activating PIK3CA mutations and delineation of the natural history and phenotype. 6
29446767 2018
2
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. 6
26266985 2015
3
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. 6
26266975 2015
4
Oculoectodermal syndrome is a mosaic RASopathy associated with KRAS alterations. 6
25808193 2015
5
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. 6
23100325 2013
6
De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. 6
22729223 2012
7
De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. 6
22729224 2012
8
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. 6
22729222 2012
9
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. 6
22658544 2012
10
A mosaic activating mutation in AKT1 associated with the Proteus syndrome. 6
21793738 2011
11
Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. 6
21063026 2011
12
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. 6
17673550 2007
13
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. 6
17611497 2007
14
Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. 6
17332249 2007
15
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. 6
15608678 2005
16
Mutation of the PIK3CA gene in ovarian and breast cancer. 6
15520168 2004
17
High frequency of mutations of the PIK3CA gene in human cancers. 6
15016963 2004
18
Truncating mutations of RB1CC1 in human breast cancer. 6
12068296 2002
19
Transcriptional map of 170-kb region at chromosome 11p15.5: identification and mutational analysis of the BWR1A gene reveals the presence of mutations in tumor samples. 6
9520460 1998
20
A new mutation of exon 5 of the P53 gene in breast cancer. 6
8364550 1993
21
Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. 6
1673792 1991
22
The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231. 6
3627975 1987
23
Antitumor activities of carboplatin-doxorubicin-ZnO complexes in different human cancer cell lines (breast, cervix uteri, colon, liver and oral) under UV exposition. 61
33491496 2021
24
Tryptanthrin exerts anti-breast cancer effects both in vitro and in vivo through modulating the inflammatory tumor microenvironment. 61
33151167 2021
25
Fabrication and evaluation of nanocontainers for lipophilic anticancer drug delivery in 3D in vitro model. 61
32945122 2021
26
Organotin derivatives of cholic acid induce apoptosis into breast cancer cells and interfere with mitochondrion; Synthesis, characterization and biological evaluation. 61
33472044 2021
27
In situ supported Pd NPs on biodegradable chitosan/agarose modified magnetic nanoparticles as an effective catalyst for the ultrasound assisted oxidation of alcohols and activities against human breast cancer. 61
33444653 2021
28
Novel silver glycinate conjugate with 3D polymeric intermolecular self-assembly architecture; an antiproliferative agent which induces apoptosis on human breast cancer cells. 61
33461021 2021
29
Cytotoxicity of botanicals and isolated phytochemicals from Araliopsis soyauxii Engl. (Rutaceae) towards a panel of human cancer cells. 61
33166626 2021
30
Rapid Response of Breast Cancer Cutaneous Metastasis to Single-Agent Palbociclib: A Case Report. 61
33540405 2021
31
Synthesis of Bioactive Diarylheptanoids from Alpinia officinarum and Their Mechanism of Action for Anticancer Properties in Breast Cancer Cells. 61
33587631 2021
32
2-Methoxy-1,4-Naphthoquinone (MNQ) Inhibits Glucose Uptake and Lactate Production in Triple-Negative Breast Cancer Cells. 61
33576213 2021
33
A bismuth diethyldithiocarbamate compound induced apoptosis via mitochondria-dependent pathway and suppressed invasion in MCF-7 breast cancer cells. 61
33555494 2021
34
Cu(I) complexes as new antiproliferative agents against sensitive and doxorubicin resistant colorectal cancer cells: synthesis, characterization, and mechanisms of action. 61
33470993 2021
35
Synthesis of MeON-Glycoside Derivatives of Oleanolic Acid by Neoglycosylation and Evaluation of Their Cytotoxicity Against Selected Cancer Cell Lines. 61
33540945 2021
36
Synthesis, structural characterization, docking simulation and in vitro antiproliferative activity of the new gold(III) complex with 2-pyridineethanol. 61
33246642 2021
37
First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies. 61
33594602 2021
38
Disruption of the Microtubule Network and Inhibition of VEGFR2 Phosphorylation by Cytotoxic N,O-Coordinated Pt(II) and Ru(II) Complexes of Trimethoxy Aniline-Based Schiff Bases. 61
33554592 2021
39
Cytotoxic Physalins from Aeroponically Grown Physalis acutifolia. 61
33586438 2021
40
Cashew apple (Anacardium occidentale L.) extract from a by-product of juice processing: assessment of its toxicity, antiproliferative and antimicrobial activities. 61
33568870 2021
41
Diketopiperazine-Based, Flexible Tadalafil Analogues: Synthesis, Crystal Structures and Biological Activity Profile. 61
33546456 2021
42
A photoactivatable Ru (II) complex bearing 2,9-diphenyl-1,10-phenanthroline: A potent chemotherapeutic drug inducing apoptosis in triple negative human breast adenocarcinoma cells. 61
33197429 2021
43
Spatiotemporal Concurrent Liberation of Cytotoxins from Dual-Prodrug Nanomedicine for Synergistic Antitumor Therapy. 61
33525873 2021
44
Dihydroquinoline derivative as a potential anticancer agent: synthesis, crystal structure, and molecular modeling studies. 61
31900682 2021
45
Hydrodynamic assisted multiparametric particle spectrometry. 61
33574415 2021
46
Half-Sandwich Ru(p-cymene) Compounds with Diphosphanes: In Vitro and In Vivo Evaluation As Potential Anticancer Metallodrugs. 61
33570919 2021
47
Antimicrobial and cytotoxic effects of ammonium derivatives of diterpenoids steviol and isosteviol. 61
33461146 2021
48
Unravelling the anticancer potency of 1,2,4-triazole-N-arylamide hybrids through inhibition of STAT3: synthesis and in silico mechanistic studies. 61
32830299 2021
49
Molecular changes associated with the anticancer effect of sulforaphane against Ehrlich solid tumour in mice. 61
33094879 2021
50
Antiproliferative and Pro-Apoptotic Effects of Thiazolo[3,2-b][1,2,4]triazoles in Breast and Cervical Cancer Cells. 61
33573578 2021

Variations for Breast Adenocarcinoma

ClinVar genetic disease variations for Breast Adenocarcinoma:

6 (show all 11)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 RB1CC1 nsv1067860 Deletion Pathogenic 3976 8:53536328-53598019 8:52623768-52685459
2 RB1CC1 nsv1067861 Deletion Pathogenic 3977 8:53537321-53574220 8:52624761-52661660
3 SLC22A18 NM_002555.6(SLC22A18):c.864_865ins[NC_000011.10:g.2919738_2919848] Insertion Pathogenic 6976
4 TP53 NM_000546.5(TP53):c.451C>A (p.Pro151Thr) SNV Pathogenic 12369 rs28934874 17:7578479-7578479 17:7675161-7675161
5 TP53 NM_000546.6(TP53):c.451C>T (p.Pro151Ser) SNV Pathogenic 12370 rs28934874 17:7578479-7578479 17:7675161-7675161
6 KRAS NM_004985.5(KRAS):c.38G>A (p.Gly13Asp) SNV Pathogenic 12580 rs112445441 12:25398281-25398281 12:25245347-25245347
7 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg) SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
8 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu) SNV Pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
9 PIK3CA NM_006218.4(PIK3CA):c.1636C>G (p.Gln546Glu) SNV Pathogenic 13654 rs121913286 3:178936094-178936094 3:179218306-179218306
10 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
11 AKT1 NM_005163.2(AKT1):c.49G>A (p.Glu17Lys) SNV Pathogenic 13983 rs121434592 14:105246551-105246551 14:104780214-104780214

Expression for Breast Adenocarcinoma

Search GEO for disease gene expression data for Breast Adenocarcinoma.

Pathways for Breast Adenocarcinoma

Pathways related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 194)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.33 TP53 TNF PIK3CA MYC MMP9 KRAS
2
Show member pathways
14.21 TP53 TNFSF11 TNF PIK3CA MYC MMP9
3
Show member pathways
14.03 TP53 TNF MYC MMP9 MMP2 KRAS
4
Show member pathways
14.01 TP53 TNFSF11 TNF MYC KRAS ESR1
5
Show member pathways
13.89 TP53 RB1CC1 MYC MMP9 MMP2 KRAS
6
Show member pathways
13.86 TP53 TNFSF11 TNF MYC KRAS ERBB2
7
Show member pathways
13.73 TP53 TNF PIK3CA MYC KRAS ERBB2
8
Show member pathways
13.67 TNF PIK3CA MMP9 MMP2 KRAS ERBB2
9
Show member pathways
13.65 TP53 TNF RB1CC1 PIK3CA KRAS CYCS
10
Show member pathways
13.61 TP53 PIK3CA KRAS ERBB2 EGFR EGF
11
Show member pathways
13.61 TP53 TNFSF11 TNF KRAS ERBB2 EGFR
12
Show member pathways
13.56 PIK3CA MYC MMP9 MMP2 KRAS EGFR
13
Show member pathways
13.55 TP53 TNFSF11 TNF PIK3CA MYC MMP9
14
Show member pathways
13.51 TNFSF11 TNF KRAS ERBB2 EGFR EGF
15
Show member pathways
13.45 TNF KRAS ESR1 ERBB2 EGFR EGF
16
Show member pathways
13.44 TNF PIK3CA KRAS CYCS CASP8 BAX
17
Show member pathways
13.43 TP53 TNF MYC KRAS ERBB2 EGFR
18
Show member pathways
13.28 TP53 PIK3CA ERBB2 EGFR EGF CASP9
19
Show member pathways
13.25 TP53 TNFSF11 TNF PIK3CA MMP9 KRAS
20
Show member pathways
13.14 TP53 TNF PIK3CA MYC KRAS ERBB2
21
Show member pathways
13.13 TP53 TNF PIK3CA MYC MMP9 KRAS
22
Show member pathways
13.12 TP53 TNF PIK3CA MYC KRAS EGFR
23
Show member pathways
13.07 PIK3CA KRAS ERBB2 EGFR EGF AKT1
24
Show member pathways
13.06 PIK3CA KRAS ERBB2 EGFR EGF AKT1
25
Show member pathways
13.05 TP53 TNF PIK3CA MYC CYCS CASP9
26
Show member pathways
13.03 PIK3CA KRAS ERBB2 EGFR CASP9 AKT1
27 13.03 TP53 TNF PIK3CA CYCS CASP9 CASP8
28
Show member pathways
13 TP53 TNF PIK3CA CYCS CASP9 BAX
29
Show member pathways
12.98 TP53 PIK3CA MYC MMP9 KRAS ERBB2
30
Show member pathways
12.97 TNF PIK3CA MYC CYCS CASP9 CASP8
31 12.97 TP53 TNF MYC KRAS ERBB2 EGFR
32
Show member pathways
12.96 TP53 PIK3CA KRAS ERBB2 EGFR EGF
33
Show member pathways
12.93 TP53 PIK3CA KRAS ESR1 ERBB2 CYCS
34
Show member pathways
12.92 TP53 MYC ESR1 CYCS CASP9 CASP8
35
Show member pathways
12.92 TP53 TNFSF11 PIK3CA MYC KRAS ESR1
36
Show member pathways
12.91 TNF PIK3CA MYC KRAS AKT1
37
Show member pathways
12.9 TNF KRAS EGFR EGF CYCS CASP9
38
Show member pathways
12.9 TP53 TNF PIK3CA MYC KRAS CYCS
39
Show member pathways
12.89 PIK3CA MMP9 MMP2 KRAS ESR1 EGFR
40
Show member pathways
12.88 PIK3CA KRAS EGFR EGF AKT1
41
Show member pathways
12.87 TP53 TNF KRAS EGFR EGF AKT1
42
Show member pathways
12.85 TP53 PIK3CA MYC KRAS ERBB2 EGFR
43
Show member pathways
12.8 PIK3CA MMP2 KRAS EGFR AKT1
44
Show member pathways
12.8 TNF PIK3CA KRAS EGFR EGF AKT1
45
Show member pathways
12.8 PIK3CA EGFR EGF CYCS CASP9 BAX
46
Show member pathways
12.79 TNFSF11 TNF CYCS CASP9 CASP8 AKT1
47 12.77 TP53 PIK3CA MYC MMP9 KRAS ERBB2
48
Show member pathways
12.75 TNF PIK3CA KRAS CASP9 AKT1
49
Show member pathways
12.74 TP53 TNF PIK3CA KRAS ERBB2 EGFR
50
Show member pathways
12.73 TNFSF11 PIK3CA MYC KRAS ESR1 ERBB2

GO Terms for Breast Adenocarcinoma

Cellular components related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.61 TP53 MYC MMP2 KRAS CYCS CASP9
2 protein-containing complex GO:0032991 9.17 TP53 MYC ESR1 EGFR CASP9 CASP8

Biological processes related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.26 TP53 TNFSF11 TNF MYC ESR1 EGFR
2 apoptotic process GO:0006915 10.19 TP53 CYCS CASP9 CASP8 BAX AKT1
3 positive regulation of cell proliferation GO:0008284 10.16 MYC KRAS ERBB2 EGFR EGF AKT1
4 positive regulation of transcription, DNA-templated GO:0045893 10.16 TP53 TNF MYC ESR1 EGFR EGF
5 negative regulation of apoptotic process GO:0043066 10.15 TP53 RB1CC1 MYC MMP9 EGFR AKT1
6 heart development GO:0007507 10.03 TP53 RB1CC1 ERBB2 CASP8
7 MAPK cascade GO:0000165 9.99 TNF MYC KRAS ERBB2 EGFR EGF
8 regulation of apoptotic process GO:0042981 9.97 TP53 ESR1 CASP9 CASP8 BAX AKT1
9 positive regulation of DNA-binding transcription factor activity GO:0051091 9.95 TNFSF11 TNF ESR1 AKT1
10 response to estradiol GO:0032355 9.94 ESR1 EGFR CASP9 CASP8
11 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.92 TNF CASP9 CASP8 BAX
12 positive regulation of gene expression GO:0010628 9.92 TP53 TNFSF11 TNF MYC KRAS ERBB2
13 apoptotic signaling pathway GO:0097190 9.91 TNF CASP8 BAX
14 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.91 TNF PIK3CA EGFR AKT1
15 positive regulation of apoptotic process GO:0043065 9.91 TP53 TNF MMP9 CASP9 CASP8 BAX
16 cellular response to drug GO:0035690 9.9 TP53 MYC EGFR
17 cellular response to growth factor stimulus GO:0071363 9.9 ERBB2 EGFR AKT1
18 positive regulation of epithelial cell proliferation GO:0050679 9.9 MYC ERBB2 EGFR
19 glucose metabolic process GO:0006006 9.9 TNF PIK3CA AKT1
20 liver development GO:0001889 9.9 RB1CC1 PIK3CA KRAS EGFR
21 positive regulation of protein localization to plasma membrane GO:1903078 9.89 TNF EGFR AKT1
22 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043280 9.88 TNF MYC CYCS
23 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.88 TNF MMP9 MMP2
24 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.88 TNF CASP9 BAX
25 extrinsic apoptotic signaling pathway GO:0097191 9.88 TNF CASP8 BAX
26 cellular response to organic cyclic compound GO:0071407 9.88 TNF CASP9 CASP8 AKT1
27 positive regulation of smooth muscle cell proliferation GO:0048661 9.88 TNF MMP2 EGFR AKT1
28 cellular response to epidermal growth factor stimulus GO:0071364 9.87 ERBB2 EGFR AKT1
29 negative regulation of Notch signaling pathway GO:0045746 9.87 EGFR EGF AKT1
30 protein kinase B signaling GO:0043491 9.87 TNF PIK3CA AKT1
31 positive regulation of neuron apoptotic process GO:0043525 9.87 TP53 TNF CASP9 BAX
32 cellular response to cadmium ion GO:0071276 9.86 MMP9 EGFR AKT1
33 phosphatidylinositol 3-kinase signaling GO:0014065 9.86 PIK3CA ERBB2 AKT1
34 negative regulation of mitotic cell cycle GO:0045930 9.86 TP53 TNF EGFR
35 cellular response to UV GO:0034644 9.86 TP53 MYC CASP9 BAX
36 negative regulation of fibroblast proliferation GO:0048147 9.85 TP53 MYC BAX
37 ERK1 and ERK2 cascade GO:0070371 9.84 TNFSF11 MYC EGF
38 response to antibiotic GO:0046677 9.84 TP53 CASP9 CASP8
39 positive regulation of phosphorylation GO:0042327 9.83 TNFSF11 EGFR EGF
40 regulation of cell motility GO:2000145 9.83 ERBB2 EGFR EGF
41 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.83 TNF CASP8 BAX
42 epidermal growth factor receptor signaling pathway GO:0007173 9.83 PIK3CA EGFR EGF AKT1
43 positive regulation of release of cytochrome c from mitochondria GO:0090200 9.81 TP53 MMP9 BAX
44 response to gamma radiation GO:0010332 9.81 TP53 MYC BAX
45 execution phase of apoptosis GO:0097194 9.8 CASP9 CASP8 AKT1
46 positive regulation of nitric-oxide synthase activity GO:0051000 9.8 TNF KRAS AKT1
47 positive regulation of protein phosphorylation GO:0001934 9.8 TNF RB1CC1 MMP9 KRAS ERBB2 EGFR
48 cellular response to reactive oxygen species GO:0034614 9.78 MMP9 MMP2 EGFR AKT1
49 mammary gland alveolus development GO:0060749 9.77 TNFSF11 ESR1 EGF
50 vagina development GO:0060068 9.73 ESR1 BAX

Molecular functions related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.63 TP53 RB1CC1 ESR1 EGFR CASP9 AKT1
2 tumor necrosis factor receptor binding GO:0005164 9.43 TNFSF11 TNF CASP8
3 identical protein binding GO:0042802 9.4 TP53 TNFSF11 TNF MMP9 KRAS ESR1
4 cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097199 9.32 CASP9 CASP8
5 nitric-oxide synthase regulator activity GO:0030235 9.13 ESR1 EGFR AKT1

Sources for Breast Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....